- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05741229
The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns
January 29, 2024 updated by: Marwa Mohamed Farag, Alexandria University
The Effect Of Nebulizied Nitroglycerin As An Adjuvant Drug In Management Of Persistent Pulmonary Hypertension Of Newborns
This aim of the study is to evaluate the effect of nebulized nitroglycerin on echocardiographic (biventricular function, pulmonary artery pressure, PDA and PFO shunting and tissue doppler imaging) and clinical parameters (Oxygen saturation index, heart rate, blood pressure, mean airway pressure, ventilation setting) in patients with PPHN.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marwa M Farag, PhD
- Phone Number: +2 01288681788
- Email: d.marwa.farag@gmail.com
Study Locations
-
-
-
Alexandria, Egypt, 0325
- Recruiting
- Alexandria University
-
Contact:
- Marwa M Farag
- Phone Number: 01288681788
- Email: d.marwa.farag@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 hour to 1 week (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Infants ≤72 hours' old, ≥37 weeks of gestation, ≥50% FiO2 need despite lung recruitment, abnormal oxygen saturation index or echocardiographic signs of PPHN will be enrolled in the trial.
Exclusion Criteria:
• Diagnosis of PPHN discovered after more than 72 hours.
- Failure of used medications and need to administrate milrinone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group I (nebulized nitroglycerine)
Patients with persistent pulmonary hypertension (PPHN) and will receive nebulized nitroglycerine as an adjuvant therapy for PPHN
|
Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
|
Placebo Comparator: Group II (conentional treatment group)
Patients with PPHN and will be treated with conventional regimen for PPHN
|
patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimation of Pulmonary artery pressure (PAP)
Time Frame: first 7 days of life
|
Systolic pulmonary artery pressure (SPAP) can be estimated by measuring the peak velocity of tricuspid valve regurgitation with the use of the modified Bernoulli's equation.
|
first 7 days of life
|
Right ventricular (RV) function in ml/kg/min
Time Frame: first 7 days of life
|
• RV output and stroke distance in main pulmonary artery:
|
first 7 days of life
|
Left ventricular (LV)function in ml/kg/min
Time Frame: first 7 days of life
|
LV output and stroke distance in ascending aorta:
|
first 7 days of life
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Hesham Ghazal, PhD, Alexandria University
- Study Director: Aly Mohamed Abdel-Mohsen, PhD, Alexandria University
- Principal Investigator: Moataz Shawky Rezk, MD, Alexandria University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2023
Primary Completion (Estimated)
August 20, 2024
Study Completion (Estimated)
August 20, 2024
Study Registration Dates
First Submitted
February 14, 2023
First Submitted That Met QC Criteria
February 14, 2023
First Posted (Actual)
February 23, 2023
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0201737
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent Pulmonary Hypertension of the Newborn
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPulmonary Hypertension, Familial Persistent, of the NewbornUnited States, Belgium, United Kingdom, Spain, Denmark, Germany, Sweden, Canada, France, Italy, Netherlands, Norway
-
Sohag UniversityCompletedPersistent Pulmonary Hypertension of the Newborn | PPHN | Persistent Fetal CirculationEgypt
-
Shandong UniversityWest China Second University HospitalNot yet recruitingPersistent Pulmonary Hypertension of the NewbornChina
-
United TherapeuticsTerminatedPersistent Pulmonary Hypertension of the NewbornUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...WithdrawnPersistent Pulmonary Hypertension of the Newborn
-
ActelionTerminatedPersistent Pulmonary Hypertension of the NewbornUnited States, Australia, Belgium, Czech Republic, France, Germany, Korea, Republic of, Poland, Russian Federation, Singapore, Switzerland, United Kingdom
-
Emory UniversityCompletedPulmonary HypertensionUnited States
-
Medical College of WisconsinRecruitingPersistent Pulmonary Hypertension of the NewbornUnited States
-
University Hospital, ToulouseCompletedPersistent Pulmonary Hypertension of the NewbornFrance
-
University of LeicesterUniversity Hospitals, Leicester; British Heart Foundation; Heart Link Children...CompletedPersistent Pulmonary Hypertension of the NewbornUnited Kingdom
Clinical Trials on Nebulized nitroglycerine as adjunctive therapy
-
Aziende Chimiche Riunite Angelini Francesco S.p.AHippocrates ResearchRecruiting
-
Brown UniversityButler HospitalCompleted
-
Region ÖstergötlandRecruitingBehavioral Symptoms | Emotional InstabilitySweden
-
Guangzhou Psychiatric HospitalUnknownDepressive Disorder | Light TherapyChina
-
Cerevast Therapeutics, Inc.Terminated
-
Microvention-Terumo, Inc.RecruitingCerebrovascular StrokeGermany, Switzerland
-
Chang Gung Memorial HospitalCompletedChild Development | Developmental Delay | Early Intervention
-
Shanghai Gynecologic Oncology GroupFudan University; Shanghai Zhongshan Hospital; Shanghai Jiao Tong University...CompletedFallopian Tube Cancer | Primary Peritoneal Carcinoma | Bulky Stage IIIC and IV Epithelial Ovarian CancerChina
-
Boston UniversityNational Institute of Mental Health (NIMH)Not yet recruitingStress Disorders, Post-TraumaticUnited States